A Phase 2 Study of Pasireotide in People With Prolactinoma

Full Title

Pasireotide Treatment for Patients with Prolactinomas Who Need Treatment Beyond Dopamine Agonist Therapy

Purpose

The purpose of this study is to see if the drug pasireotide works well to treat prolactinomas. Prolactinomas are noncancerous pituitary gland tumors that make too much prolactin. Prolactin is a hormone that causes the body to make less estrogen and testosterone (sex hormones).

The people in this study have prolactinoma that keeps growing or has only partially responded to dopamine agonist therapy. Dopamine agonists are drugs that stop your body from making too much prolactin. They can shrink prolactinomas.

Pasireotide attaches to somatostatin receptors (SSTRs), which are proteins that play a role in decreasing hormones, including prolactin. After attaching to SSTRs, pasireotide reduces prolactin production. It is given as an injection into the buttock muscle every 4 weeks.

Contact

For more information and to see if you can join this study, please call Dr. Eliza Geer’s office at 646-608-3797.